Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT05622227

68Ga PET/CT Imaging in Breast Cancer Patients

Conditions: Breast Cancer

Sex: All
Ages: 18 Years – 80 Years
Phase: PHASE1, PHASE2
Enrollment: 50
Sponsor: Peking Union Medical College Hospital

Location: China

Summary

PSMA is highly expressed on the cell surface of the microvasculature of several solid tumors, including breast cancer. This makes it a potentially imaging target for the detection and grading of breast cancer. This pilot study was designed to evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 18F-FDG in the same group of breast cancer patients.

Eligibility Criteria

Inclusion Criteria:breast cancer patients highly suggested by ultrasound or histologically confirmed;68Ga-P16-093 PET/CT and 18F-FDG within two weeks;signed written consent.Exclusion Criteria:known allergy against PSMA;any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05622227). StuddyBuddy aggregates publicly available trial information.